ZEUS Rapid SARS CoV-2 IgM/IgG Antibody Test System delivers
with over 98% Specificity and no demonstrated cross reactivity to other coronaviruses.
ZEUS Rapid SARS-CoV-2 IgM/IgG Antibody Test System
ZEUS Rapid SARS-CoV-2 IgM/IgG has been validated according to FDA guidelines established for serological assays, meeting the criteria to be distributed to where it is needed most and is now shipping. ZEUS Scientific has heard your requests for help and is committed to providing easy-to-use solutions that will help address the public health threat posed by COVID-19.
ZEUS Rapid SARS CoV-2 IgM/IgG has a combined Specificity of (159/161), 98.8% providing confidence in your results
- 95 healthy SARS-CoV-2 negative patients were tested with ZEUS Rapid SARS-CoV-2 IgM/IgG, and 94 tested negative demonstrating 98.9% specificity. Testing was performed in duplicate, the one discrepant sample tested negative in one of the duplicates.
- Cross-Reactivity data demonstrates ZEUS Rapid SARS-CoV-2 does not react to other coronaviruses. 5 patients that were seropositive for the following coronaviruses, OC43 (n=2), NL63 (n=2) and HKU1 (n=1) tested negative on our test.
- 61 patients that tested positive for a variety of other diseases were tested with ZEUS Rapid SARS-CoV-2, and 60 of the patients tested negative. Based on these results, our test is 98.4% specific.
ZEUS Rapid SARS-CoV-2 IgM/IgG has been tested in a normal healthy population, challenged with patients positive with other coronaviruses and further evaluated with samples taken from patients with other infections. Cross Reactivity in any of these cohorts can trigger false positive results. Regardless of the source of Cross Reactivity it is critical that tests reduce the potential of false positives. ZEUS Rapid SARS-CoV-2 is shown to be nearly 99% specific, limiting false positive results.
Why does this matter?
A false positive SARS-CoV-2 antibody test may lead to a patient believing they have specific antibodies and some protection from the virus (SARS-CoV-2). If a recent infection is suspected, a false positive result may lead to a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contacts with other potentially COVID-19 infected patients, limits in the ability to work, or other unintended adverse effects.
Test with Confidence. Test with ZEUS.